Assessment of OSA in Latin American and Response to Neuromod Therapy (Trans-Q DISE)

Assessment of Obstructive Sleep Apnea in the Latin American Population and Response to Neuromodulation Therapy to Treat Obstructive Sleep Apnea

The purpose of this study is to characterize the upper airway of Latin American subjects who have been diagnosed with moderate/severe obstructive sleep apnea (OSA) and assess response to a neuromodulation therapy to treat OSA.

Study Overview

• Status: Recruiting
• Conditions: Obstructive Sleep Apnea
• Intervention / Treatment: Diagnostic test: Drug Induced Sleep Endoscopy with PNS

• Study Type: Interventional
• Enrollment (Estimated): 50
• Phase: Early Phase 1

Contacts and Locations

• Study Contact: Name: Andrea Director of Clinical Operations; Phone Number: 866-675-4430; Email: andreas@lunairmedical.com

Study Locations

• Paraguay
  • Asunción, Paraguay
    • Recruiting
    • Sanatorio Americano
    • Contact: Medical Doctor; Phone Number: 866-675-4430; Email: andreas@lunairmedical.com

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Adult; Older Adult
• Accepts Healthy Volunteers: No

Description

Inclusion Criteria:

1. Subject is aged ≥ 18 years old
2. Subject is willing and able to provide informed consent
3. Subject is geographically stable
4. Subject does not have access to alternative Sleep Disordered Breathing treatments (e.g. oral appliances, and/or behavioral treatments)
5. Subject has an Apnea-Hypopnea Index (AHI) score ≥15 < 100 events per hour on Screening PSGs (under AASM 4%) based on in-lab polysomnography studies

Exclusion Criteria:

1. Subject is currently implanted with another active implantable device.
2. Subject is actively enrolled in another premarket investigational study (medical device or drug) unless approved by Sponsor in writing.
3. Subject is considered vulnerable such as incarcerated or cognitively impaired.
4. Subject is taking opioids, narcotics, sleep or psychotic medications or supplements that in the opinion of the investigator may alter consciousness, the pattern of respiration, sleep architecture, or with known effect on sleep-wake function or alertness.
5. Any reason for which, in the judgment of the investigator, the subject is considered to be a poor study candidate, which may include, but is not limited to: any uncontrolled neurological, medical, social, or psychological problems that could complicate the required procedures and evaluations of the study ((e.g. uncontrolled hypertension, unstable angina, uncompensated heart failure or COPD, major depression, Parkinson's disease, epilepsy)
6. Subject has previous upper respiratory tract (URT) surgery (e.g., uvula, soft palate or tonsils) within 60 days prior to Screening PSG.
7. Subject has a need for chronic supplemental oxygen therapy for any reason or a PaO2 <70 mm Hg
8. Subject has other sleep disorders or sleep hygiene behaviors that confound functional assessments of sleepiness and/or overnight PSG Study outcomes (e.g. Narcolepsy with cataplexy, idiopathic hypersomnolence, insomnia, REM sleep behavior disorder, or sleep movement disorders, such as restless leg syndrome or periodic limb movement, producing sleep disturbances unrelated to OSA.)
9. Subject has severe chronic kidney disease (GFR < 30)
10. Subject has currently excessive use of alcohol, tobacco, caffeine, or recreational drugs.
11. Subject is unwilling or unable to refrain from consumption of alcoholic beverages for 24 hours prior to the start of each PSG study.
12. Subject has a BMI > 40 kg/m2
13. Subject has an active systemic infection
14. If female, subject is pregnant at the time of enrollment or planning to become pregnant during the study time period (must have a negative serum or urine pregnancy test within 14 days prior to enrollment)
15. Subject has a tonsil size 3 or 4 based on the tonsil grading system
16. Subject has documented history of Phrenic nerve palsy or asymmetry of the diaphragm
17. Subject has any trauma to the upper airway that interferes with limited tongue movement or inability to move the tongue, tongue dysfunction, atrophy, hypertrophy, fasciculation, or problems swallowing or speaking
18. Subject has severe mandibular deficiency/retrognathia or syndromic craniofacial abnormalities.
19. Subject has previous surgical resection or radiation therapy for cancer or congenital malformations in the larynx, tongue, or throat.
20. Subject has an oxygen saturation (SaO2) >10% falls index > 15 events per hour on Screening PSGs
21. Subject has >25% central apnea events as a proportion of the sum of apnea and hypopnea events per hour on Screening PSGs (up to 3 patients with CAI+MAI ≥ 25% may be included)
22. Subject has sleep Efficiency < 80%

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Other
• Allocation: N/A
• Interventional Model: Single Group Assignment
• Masking: None (Open Label)

Number of Arms

1

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Trans-Q DISE treated subjects	Diagnostic test: Drug Induced Sleep Endoscopy with PNS; Enrolled subjects will complete an overnight PSG and then undergo a DISE procedure with a 30-minute research period.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Understand the difference in response compared to prior U.S. based studies to the response in Latin America.	Reviewing phrenic nerve stimulation response to literature of US based population	enrollment to study exit, usually within 3 weeks of screening
Use VOTE scoring to characterize the type of upper airway collapse as assessed via DISE.	Upper Airway will be characterized using VOTE scoring as assessed by a qualified, trained Independent Reviewer.	enrollment to study exit, usually within 3 weeks of screening
Use VOTE scoring and airway opening measurements to characterize the effect of Phrenic Nerve Stimulation and if it is a viable and effective treatment of OSA and correlation to phenotype.	In combination with VOTE scoring and airway opening measurements, the effects of phrenic nerve stimulation will be compared across treated patient population.	enrollment to study exit, usually within 3 weeks of screening

Collaborators and Investigators

• Sponsor: Lunair Medical

Study record dates

Study Major Dates

• Study Start (Actual): November 21, 2024
• Primary Completion (Actual): December 31, 2024
• Study Completion (Estimated): December 31, 2025

Study Registration Dates

• First Submitted: December 6, 2024
• First Submitted That Met QC Criteria: December 30, 2024
• First Posted (Actual): January 8, 2025

Study Record Updates

• Last Update Posted (Estimated): September 3, 2025
• Last Update Submitted That Met QC Criteria: September 2, 2025
• Last Verified: September 1, 2025

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Nervous System Diseases; Respiratory Tract Diseases; Respiration Disorders; Sleep Wake Disorders; Apnea; Sleep Disorders, Intrinsic; Dyssomnias; Sleep Apnea Syndromes; Sleep Apnea, Obstructive
• Other Study ID Numbers: 10081 (DAIDS ES Registry Number)

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No
• product manufactured in and exported from the U.S.: No